Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Pier Capital LLC

Pier Capital LLC decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 34.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 144,850 shares of the biopharmaceutical company's stock after selling 75,597 shares during the period. Pier Capital LLC owned approximately 0.11% of Halozyme Therapeutics worth $8,291,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of HALO. Castleark Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $3,991,000. EP Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $357,000. Stifel Financial Corp increased its holdings in shares of Halozyme Therapeutics by 126.3% during the 3rd quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company's stock worth $980,000 after buying an additional 9,555 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Halozyme Therapeutics by 6.2% during the 3rd quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company's stock worth $31,204,000 after buying an additional 31,871 shares during the last quarter. Finally, HighTower Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 20.2% during the 3rd quarter. HighTower Advisors LLC now owns 36,174 shares of the biopharmaceutical company's stock worth $2,080,000 after buying an additional 6,075 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on HALO shares. HC Wainwright restated a "buy" rating and set a $68.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, November 20th. Wells Fargo & Company cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and increased their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and increased their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $61.11.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares of the company's stock, valued at approximately $39,988,802.96. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 60,000 shares of company stock valued at $3,425,000. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Up 0.7 %

HALO stock traded up $0.34 during midday trading on Friday, hitting $48.40. The company's stock had a trading volume of 905,788 shares, compared to its average volume of 2,149,973. The firm has a market capitalization of $6.16 billion, a P/E ratio of 16.03, a PEG ratio of 0.44 and a beta of 1.23. The firm has a 50-day simple moving average of $52.43 and a 200-day simple moving average of $53.91. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.